The estimated Net Worth of Capital Management, Llcra C... is at least $33.7 Million dollars as of 15 April 2008. Capital C owns over 1,300,000 units of Curis Inc stock worth over $31,877,876 and over the last 17 years Capital sold CRIS stock worth over $1,820,000.
Capital has made over 1 trades of the Curis Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently Capital sold 1,300,000 units of CRIS stock worth $1,820,000 on 15 April 2008.
The largest trade Capital's ever made was selling 1,300,000 units of Curis Inc stock on 15 April 2008 worth over $1,820,000. On average, Capital trades about 1,300,000 units every 0 days since 2008. As of 15 April 2008 Capital still owns at least 6,250,564 units of Curis Inc stock.
You can see the complete history of Capital C stock trades at the bottom of the page.
Over the last 24 years, insiders at Curis Inc have traded over $10,321,234 worth of Curis Inc stock and bought 10,678,594 units worth $25,596,192 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Discovery Technologies Ltd ..., and James R Mcnab. On average, Curis Inc executives and independent directors trade stock every 62 days with the average trade being worth of $811,553. The most recent stock trade was executed by James E Dentzer on 27 January 2022, trading 5,500 units of CRIS stock currently worth $17,160.
curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
Curis Inc executives and other stock owners filed with the SEC include: